semaj83/ctmatch_classification huggingface dataset:
Patient description: An 89-year-old man was brought to the emergency department by his wife and son after six months of progressive changes in cognition and personality. He began to have poor memory, difficulty expressing himself, and exhibited unusual behaviors, such as pouring milk onto the table and undressing immediately after getting dressed. He is unable to dress, bathe, use the toilet, or walk independently. On examination the patient's temperature was 36.5C (97.7F), the heart rate 61 bpm in an irregular rhythm, the blood pressure 144/78 mm Hg, and the respiratory rate 18 bpm. The patient was alert and oriented to self and city but not year. He frequently interrupted the examiner. He repeatedly reached out to grab things in front of him, including the examiner's tie and face. He could not spell the word "world" backward, could not follow commands involving multiple steps and was unable to perform simple calculations. His speech was fluent, but he often used similar-sounding word substitutions. He could immediately recall three out of three words but recalled none of them after 5 minutes. Examination of the cranial nerves revealed clinically significant paratonic rigidity. Myoclonic jerks were seen in the arms, with symmetrically brisk reflexes. The reflexes in

Clinical trial eligibility criteria: eligible ages (years): 50.0-90.0,  Memory Disorders Mild Cognitive Impairment Alzheimer's Disease A diagnosis of mild cognitive impairment due to Alzheimer's disease (MCI due to AD) by the patient's referring clinician per recent National Institutes of Aging-Alzheimer's Association (Albert et al., 2011) A diagnosis of mild Alzheimer's disease by the patient's referring clinician per recent National Institutes of Aging-Alzheimer's Association (McKhann et al., 2011) 90 years of age  Younger than the age of 50 or older than the age of 90 Any self-reported history of substance abuse or alcohol abuse Any self-reported history of prior head trauma (e.g., stroke, traumatic brain injury) Any prior self-reported history of significant depression or other mood disorder
Patient description: An 89-year-old man was brought to the emergency department by his wife and son after six months of progressive changes in cognition and personality. He began to have poor memory, difficulty expressing himself, and exhibited unusual behaviors, such as pouring milk onto the table and undressing immediately after getting dressed. He is unable to dress, bathe, use the toilet, or walk independently. On examination the patient's temperature was 36.5C (97.7F), the heart rate 61 bpm in an irregular rhythm, the blood pressure 144/78 mm Hg, and the respiratory rate 18 bpm. The patient was alert and oriented to self and city but not year. He frequently interrupted the examiner. He repeatedly reached out to grab things in front of him, including the examiner's tie and face. He could not spell the word "world" backward, could not follow commands involving multiple steps and was unable to perform simple calculations. His speech was fluent, but he often used similar-sounding word substitutions. He could immediately recall three out of three words but recalled none of them after 5 minutes. Examination of the cranial nerves revealed clinically significant paratonic rigidity. Myoclonic jerks were seen in the arms, with symmetrically brisk reflexes. The reflexes in

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dementia Patients aged 18 years and over Registered with a participating general practice during the study period Minimum one year of records prior to study entry meeting CPRD data quality Followed on or after 1 January 1997  Patients without recorded gender Less than 1 year of follow-up between study entry and date of administrative censoring
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 13.0-999.0,  Cryptosporidiosis HIV Infections Patients must have Documented HIV infection Intestinal cryptosporidiosis Willingness to undergo a 1 week washout phase of all anticryptosporidial medications and stabilization on a protocol directed, antidiarrheal regimen Greater than or equal to 4 stools per day, on average, for a minimum of 21 out of 28 days prior to study entry, secondary to cryptosporidiosis AS PER 2/10/97 Four or more stools per day, on average, during the 5-day screening period prior to baseline  Co-existing Condition Patients with the following symptoms and conditions are excluded Inability to tolerate oral medications Life expectancy less than 3 months in the opinion of the investigator Active CMV colitis, C. difficile colitis, giardiasis, salmonellosis, shigellosis, campylobacteriosis, inflammatory bowel disease, diarrhea secondary to another documented intestinal pathogen, or active or uncontrolled MAC disease, defined as symptomatic MAC disease and/or a patient who is not on appropriate anti-MAC therapy in the presence of MAC disease NOTE Patients who have been treated for MAC disease for at least 4 weeks and have resolved their symptoms may be enrolled. Patients dually infected with microsporidiosis may be randomized to the study but will not count toward the sample size AS PER 2/10/97 Failure to record a minimum of four days of information on the use of antidiarrheal medication and the frequency of bowel movements in the daily diary during the screening period Allergy to corn or corn products
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Infections Cytopenias Concurrent Treatment Allowed Minimal local irradiation for tumors Patients must have Diagnosis of AIDS or AIDS related complex (ARC) Neutropenia, due either to zidovudine (AZT) or HIV infection Life expectancy = or > 6 months  Co-existing Condition Patients with the following conditions or symptoms are excluded Significant malabsorption as defined by greater than 10 percent weight loss and one or more of the following Serum carotene less than 75 IU/ml Vitamin A level less than 75 IU/ml More than 4 foul-smelling or greasy stools per day Other of malabsorption Kaposi's sarcoma (KS) or other tumor which is likely to require specific antitumor therapy during study, other than minimal local irradiation Active, life-threatening infection with bacterial, viral, fungal, or protozoan pathogens or fever of 39 degrees C within 10 days of study entry, unless it is apparent that the fever is not due to a severe underlying infection Concurrent Medication
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Infections Cytopenias Patients must have Serum antibody to HIV with or without evidence of HIV antigenemia White blood cells (WBC) = or < 4500 cells/mm3 measured on at least 2 occasions separated by a minimum of 1 week Qualifying indications for AZT therapy Life expectancy = or > 6 months  Co-existing Condition Patients with the following conditions or symptoms are excluded Current or past history of malignancy including Kaposi's sarcoma Excessive diarrhea or significant malabsorption If patients have had > 10 percent weight loss within the past 3 months, they should not have malabsorption as evidenced by serum carotene < 75 IU/ml, serum vitamin A < 75 IU/ml, significant malabsorption 4 foul-smelling or greasy stools per day or other criteria Currently hospitalized or hospitalized within the last 4 weeks for the treatment of opportunistic infection (IO) Less than 1 week since completing treatment of Pneumocystis carinii pneumonia (PCP) Active OI requiring systemic treatment Evidence of nutritional deficiencies that may contribute to anemia and/or leukopenia Concurrent Medication
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Protozoan Infections HIV Infections Concurrent Medication Required If coincident enteric pathogens that are not eradicable (i.e., Mycobacterium avium complex) are detected, they should be treated appropriately and the patient must be on a stable regimen of therapy for at least two weeks Allowed Patients taking antidiarrheal medications must be on a stable regimen for at least seven days prior to randomization Patients taking other concomitant medications, including antiretrovirals, must be on a stable regimen for two weeks prior to randomization Patients must have HIV positive status. Written documentation (for example, patient's chart) of HIV diagnosis is acceptable in lieu of repeat testing. Confirmation by Western blot is not necessary Biopsy-proven microsporidiosis of the fourth portion of the duodenum or proximal jejunum within 90 days before randomization Average of > 3 liquid bowel movements per day over 7 consecutive days immediately prior to randomization, with an average volume > 500 ml per day over three or more consecutive days immediately prior to randomization, as documented by data collected in a daily diary. NOTE  Co-existing Condition Patients with the following symptoms or conditions are excluded Grade 4 neutropenia Decompensated liver disease Positive toxin analysis for C. difficile Positive microscopic examination for Giardia lamblia, Entamoeba histolytica, and Isospora belli Positive on culture for Shigella, Salmonella, Yersinia and Campylobacter Positive fluorescent antibody test for Cryptosporidium Evidence of CMV on small bowel biopsy, flexible sigmoidoscopic or colonoscopic biopsies within 90 days of randomization Any other condition that, in the opinion of the investigator, makes the patient unsuitable for study entry
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cryptosporidiosis HIV Infections Concurrent Medication Allowed Antidiarrheal compounds (if dose remains stable) Zidovudine (AZT), dideoxyinosine (ddI), dideoxycytidine (ddC), or alternative HIV therapy (provided dose was stable for at least 4 weeks prior to study entry) Patients must have AIDS Cryptosporidium parvum enteritis Chronic diarrhea Life expectancy of at least 4 weeks Ability to tolerate food by mouth  Co-existing Condition Patients with the following symptoms or conditions are excluded Concurrent unresolved clinical infections with enteric pathogens other than C. parvum (e.g., rotavirus, Salmonella, Shigella, Campylobacter, Giardia, C. difficile toxin, Yersinia, amebiasis, MAI, CMV, Microsporida) as determined by history or routine microbiology screening Other acute infections or concurrent immediately life-threatening medical crisis other than cryptosporidiosis Grossly bloody diarrhea Known allergy to milk or milk products (other than lactose intolerance) Prior Medication Excluded Other experimental therapy (e.g., macrolide antibiotics, paromomycin) within 30 days prior to study entry
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  HIV Infections Patients must have AIDS diagnosis according to CDC criteria CD4 count less than or equal to 200 cells/mm3 or CD4 count greater than or equal to 200 cells/mm3 and documented cryptosporidiosis for a minimum of 4 weeks Cryptosporidial diarrhea as defined by (1) presence of Cryptosporidium oocytes in a stool specimen within 14 days of enrollment; and (2) chronic diarrhea (i.e., an average of at least 4 bowel movements per day for a minimum of 2 weeks) Life expectancy of at least 1 month Ability to tolerate food by mouth Prior Medication Required Any anti-diarrheal or anti-emetic medication for which the dosage regimen has been stable for at least 1 week prior to enrollment  Co-existing Condition Patients with the following symptoms or conditions are excluded Grade 4 (hematologic) or Grade 3 (for all others) toxicity. (Patients with Grade 3 toxicity for hepatic parameters may be enrolled if, in the investigator's judgment, the abnormalities are due to biliary cryptosporidiosis.) Patients with the following prior conditions are excluded Presence of Salmonella, Shigella, Campylobacter, Yersinia, Giardia lamblia, Entamoeba histolytica, Microsporidia, Isospora, Cyclospora, or Clostridium difficile toxin in stool (based on assessment within 14 days prior to enrollment by stool ova and parasite examination, culture, and C. difficile assay) History of intestinal Mycobacterium avium intracellular infection or intestinal Kaposi's sarcoma History of Cytomegalovirus colitis, unless 28 days of therapy with ganciclovir or foscarnet completed subsequent to diagnosis Prior Medication Excluded Investigational drug therapy within 14 days of enrollment, unless available under an FDA-authorized expanded access program
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 55.0-999.0,  Diarrhea Gastrointestinal Diseases years or older primary source of drinking water used at home is supplied by Sonoma County Water Agency without use of home filtration device or bottled water all individuals living in the home must sign informed consent and agree to have the water treatment device installed no known immunocompromising conditions (including HIV/AIDS, active cancer, or transplant recipients)  persons with immunocompromising condition (including HIV/AIDS, active cancer, or transplant recipients) employees and family members of the Sonoma County Water Agency or a Sonoma County Water District
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vaginosis, Bacterial Premature Birth Birth Weight Chorioamnionitis African American, Hispanic, Asian/Pacific Islander, Native American, and white women  Women with a prior preterm delivery, multiple gestation, chronic hypertension or pre-existing diabetes, antibiotic use before enrollment in the study, allergy to metronidazole, history of alcohol abuse in past year, and women under age 18
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 6.0-17.0,  Crohn Disease Between the ages of 6 and 17 years Have had Crohn's disease diagnosed for at least 3 months prior to screening, with gastritis, duodenitis, colitis, ileitis, or ileocolitis, previously confirmed by endoscopy and biopsy Have active Crohn's disease despite adequate current treatment with an immunomodulator (ie, AZA, 6-MP, or MTX)  Disease complications for which surgery might be indicated Surgery for bowel diversion with placement of a stoma within 3 months prior to screening Positive stool examination for enteric pathogens including Giardia lamblia, Clostridium difficile, Shigella species, and Salmonella species
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Extrahepatic Bile Duct Cancer Gallbladder Cancer Liver Cancer Diagnosis of cancer of the biliary tract by 1 of the following methods Histologic confirmation Stenosis of the biliary tract by MRI, CT scan, or ECHO Unresectable disease Amenable to radiotherapy No visceral metastases by imaging Hepatic adenopathies that can be included in a radiation field allowed No known ampulla of Vater or pancreatic cancer involving the biliary tract WHO performance status 0-2 Creatinine < 1.5 mg/dL
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Healthy Healthy male subjects Caucasian origin Age: between 18 and 55 years (inclusive) Body mass index (BMI) within 18-30 kg/m² Body weight at least 50 kg, at most 100 kg Non-smoker (or ex-smoker ≥1 year), proven by urine cotinine <500 ng/ml Clinically acceptable supine blood pressure and pulse rate, i.e. BP 100-145 mmHg systolic, 60-90 mmHg diastolic and pulse rate 50-100 bpm Normal ECG Participants must perform an adequate contraception during the study and until 6 months after the last dose of the present trial Ability to communicate well with the investigator and comply with the requirements of the entire study  Subjects with contraindications for budesonide Subjects with contraindications for metronidazole History or current clinical evidence of any cardiac, cardio-vascular, pulmonary, gastrointestinal, (cholangio-)hepatic, renal, endocrine, neurological, musculoskeletal, ophthalmological, infectious, haematological, oncological, psychiatric, or other acute or chronic diseases and/or pathological findings which might interfere with the drugs' safety, tolerability, absorption and/or pharmacokinetics History or current evidence of clinically relevant allergies or idiosyncrasy to drugs or food Clinically relevant abnormalities in clinical chemical, hematological or any other laboratory variables Current smoker or ex-smoker ≤ 1 year Excessive alcohol consumption (³ 35 g/day in males) Abuse of drugs Positive drug screening Positive anti-HIV-test, HBsAg-test or anti-HCV-test
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 2.0-5.0,  Helminthiasis Criteria:The are age of the child is 2-5 years old he/she has not been suffering from serious chronic illness the child stool test must be positive for STH he/she had not been taken any antehelminthic drug in the previous six months parents/guardian are agree for their child participation in the study. e -  age of the child less than 2 years old and more than 5 years old his/her stool test negative for any intestinal helminth he/she has been suffering from serious chronic illness parents/guardian are not willing to give consent for their child's participation in the study if he/she receives any antehelminthic drug after survey but before the study interventions
Patient description: A 32-year-old male presents to your office complaining of diarrhea, abdominal cramping and flatulence. Stools are greasy and foul-smelling. He also has loss of appetite and malaise. He recently returned home from a hiking trip in the mountains where he drank water from natural sources. An iodine-stained stool smear revealed ellipsoidal cysts with smooth, well-defined walls and 2+ nuclei.

Clinical trial eligibility criteria: eligible ages (years): 0.75-3.0,  Cryptosporidiosis Male and female children aged 9-36 months at the time of enrollment Presence of acute or persistent diarrhea (diarrhea defined as 3 or more loose stool in the previous 24 hours AND not considered normal for that child if the child is exclusively breast fed OR any number of bloody stools in the previous 24 hours; less than or equal to 14 days duration for acute diarrhea; >14 days duration for persistent diarrhea) Child's parent/guardian speaks English or Luganda Parent/guardian provides full and free informed consent for child to participate in study  Unknown age Known cardiac, CNS, metabolic or endocrine disorders Moribund children Children with recent history of choking or sudden onset of symptoms with suspected foreign body inhalation